# Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation

> **NCT02728206** · PHASE2 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 9 (actual)

## Conditions studied

- Hepatitis C Virus Infection

## Interventions

- **DRUG:** SOF/VEL

## Key facts

- **NCT ID:** NCT02728206
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-12
- **Primary completion:** 2018-01-16
- **Final completion:** 2018-01-16
- **Target enrollment:** 9 (ACTUAL)
- **Last updated:** 2019-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02728206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02728206, "Sofosbuvir/Velpatasvir Fixed-Dose Combination in HCV-Infected Adults Who Are Undergoing Liver Transplantation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02728206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*